JP4509999B2 - 医薬送達及び抗原提示システムとしてのペプチドナノ粒子 - Google Patents

医薬送達及び抗原提示システムとしてのペプチドナノ粒子 Download PDF

Info

Publication number
JP4509999B2
JP4509999B2 JP2006502449A JP2006502449A JP4509999B2 JP 4509999 B2 JP4509999 B2 JP 4509999B2 JP 2006502449 A JP2006502449 A JP 2006502449A JP 2006502449 A JP2006502449 A JP 2006502449A JP 4509999 B2 JP4509999 B2 JP 4509999B2
Authority
JP
Japan
Prior art keywords
peptide
nanoparticles
drug
nanoparticle
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006502449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519781A (ja
JP2006519781A5 (enExample
Inventor
ブルクハルト，ペーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32864945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4509999(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2006519781A publication Critical patent/JP2006519781A/ja
Publication of JP2006519781A5 publication Critical patent/JP2006519781A5/ja
Application granted granted Critical
Publication of JP4509999B2 publication Critical patent/JP4509999B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006502449A 2003-02-17 2004-02-16 医薬送達及び抗原提示システムとしてのペプチドナノ粒子 Expired - Fee Related JP4509999B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003551 2003-02-17
PCT/IB2004/000423 WO2004071493A1 (en) 2003-02-17 2004-02-16 Peptidic nanoparticles as drug delivery and antigen display systems

Publications (3)

Publication Number Publication Date
JP2006519781A JP2006519781A (ja) 2006-08-31
JP2006519781A5 JP2006519781A5 (enExample) 2007-03-29
JP4509999B2 true JP4509999B2 (ja) 2010-07-21

Family

ID=32864945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006502449A Expired - Fee Related JP4509999B2 (ja) 2003-02-17 2004-02-16 医薬送達及び抗原提示システムとしてのペプチドナノ粒子

Country Status (6)

Country Link
US (1) US8575110B2 (enExample)
EP (1) EP1594469B1 (enExample)
JP (1) JP4509999B2 (enExample)
AT (1) ATE371437T1 (enExample)
DE (1) DE602004008582T2 (enExample)
WO (1) WO2004071493A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート
US20040236414A1 (en) * 2003-05-23 2004-11-25 Brar Balbir S. Devices and methods for treatment of stenotic regions
US7226473B2 (en) * 2003-05-23 2007-06-05 Brar Balbir S Treatment of stenotic regions
JP5117191B2 (ja) * 2004-10-01 2013-01-09 ミダテック リミテッド 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
NZ573622A (en) 2006-06-12 2011-12-22 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US8889117B2 (en) * 2007-02-15 2014-11-18 Yale University Modular nanoparticles for adaptable vaccines
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
WO2009042895A2 (en) * 2007-09-26 2009-04-02 Dana-Farber Cancer Institute, Inc. Reagents for inducing an immune response
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
RU2540871C2 (ru) * 2008-02-01 2015-02-10 Альфа-О Пептидес Аг Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
KR101803099B1 (ko) 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
EP2313108A4 (en) * 2008-06-30 2013-06-12 Us Army As Represented By The Secretary Of The Army MALARIA VACCINE FROM SELF-ORGANIZING POLYPEPTIDE NANOTEHICLES
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
EP2397547A4 (en) 2009-02-10 2012-09-05 Univ Ryukyus DRUG CARRIER AND ADJUVANT AND VACCINE USING EACH
CA2759332A1 (en) * 2009-04-21 2010-10-28 Selecta Biosciences, Inc. Immunonanotherapeutics providing a th1-biased response
WO2010138193A2 (en) * 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
AU2010293059B2 (en) * 2009-08-26 2017-03-16 Selecta Biosciences, Inc. Compositions that induce T cell help
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP2611466B1 (en) 2010-08-30 2019-06-12 President and Fellows of Harvard College Shear controlled release of thrombolytic therapies for stenotic lesions
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
CA2851917A1 (en) 2011-10-12 2013-04-18 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
CA2910584A1 (en) 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
TW201511774A (zh) * 2013-09-18 2015-04-01 Iner Aec Executive Yuan 放射性標誌之主動標靶性醫藥組合物及其用途
US10188136B2 (en) 2016-02-16 2019-01-29 Indian Institute Of Science Education And Research Hydrophobin mimics: process for preparation thereof
EP4242298A2 (en) * 2016-12-02 2023-09-13 Taiga Biotechnologies, Inc. Nanoparticle formulations
KR101955928B1 (ko) * 2016-12-30 2019-03-08 경상대학교산학협력단 먹장어 유래 vlrb 단백질의 소수성 테일 도메인을 포함하는 다량체 다가 중합체
WO2018154010A1 (en) 2017-02-23 2018-08-30 Alpha-O Peptides Ag Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018172447A1 (en) 2017-03-23 2018-09-27 Alpha-O Peptides Ag Self-assembling protein nanoparticles with built-in six-helix bundle proteins
US11213582B2 (en) 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
AU2020274117A1 (en) 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
EP4026558A4 (en) * 2019-08-27 2022-10-19 Tokyo Institute of Technology COMPOSITE PROTEIN MONOMER HAVING A NON-STRUCTURAL PROTEIN OF VIRUS SUPPORTED THEREOF, AGGREGATE OF COMPOSITE PROTEIN MONOMER, AND COMPONENT VACCINE COMPRISING AGGREGATE AS ACTIVE INGREDIENT
CN111150842B (zh) * 2019-12-31 2023-09-05 优锐生物医药科技(深圳)有限公司 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用
CN111150841B (zh) * 2019-12-31 2023-08-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
JP2023522249A (ja) * 2020-04-22 2023-05-29 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
KR20230088732A (ko) 2020-09-29 2023-06-20 옥스포드 유니버시티 이노베이션 리미티드 뇌졸중 치료
WO2022106860A1 (en) 2020-11-20 2022-05-27 Pécsi Tudományegyetem Recombinant peptides for use in therapy
WO2023108026A2 (en) 2021-12-08 2023-06-15 Oakgrove Bio Llc Biological production of histidine-rich peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US5041385A (en) * 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
US5877279A (en) * 1994-10-13 1999-03-02 Nanoframes, Llc Materials for the production of nanometer structures and use thereof
US6756039B1 (en) * 1999-05-10 2004-06-29 The Regents Of The University Of California Self assembling proteins
WO2001000010A1 (en) * 1999-06-25 2001-01-04 Kondejewski Leslie H Polypeptide compositions formed using a coiled-coil template and methods of use
JP4085231B2 (ja) * 2000-02-28 2008-05-14 株式会社ビークル タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法

Also Published As

Publication number Publication date
DE602004008582T2 (de) 2008-05-21
ATE371437T1 (de) 2007-09-15
US20070014804A1 (en) 2007-01-18
WO2004071493A1 (en) 2004-08-26
JP2006519781A (ja) 2006-08-31
US8575110B2 (en) 2013-11-05
EP1594469B1 (en) 2007-08-29
DE602004008582D1 (de) 2007-10-11
EP1594469A1 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
JP4509999B2 (ja) 医薬送達及び抗原提示システムとしてのペプチドナノ粒子
Spicer et al. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Lee et al. Adaptations of nanoscale viruses and other protein cages for medical applications
JP5211109B2 (ja) 膜転位剤および製薬学的有効成分の複合物
Shan et al. Modularized peptides modified HBc virus-like particles for encapsulation and tumor-targeted delivery of doxorubicin
Rohovie et al. Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery
Koudelka et al. Virus-based nanoparticles as versatile nanomachines
ES2847288T3 (es) Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado
JP6553105B2 (ja) クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
US10513539B2 (en) Hydrophobic modified peptides and their use for liver specific targeting
ES2441118T3 (es) Péptidos modificados hidrófobos derivados de preS del virus de la hepatitis B (HBV), y su uso como inhibidores del acceso del HBV y el HDV
Le et al. Biodistribution of filamentous plant virus nanoparticles: pepino mosaic virus versus potato virus X
EP2257280A1 (en) Engineered tunable nanoparticles for delivery of therapeutics, diagnostics, and experimental compounds and related compositions for therapeutic use
Yildiz et al. Engineering of Brome mosaic virus for biomedical applications
ES2708662T3 (es) Péptidos hidrofóbicos modificados para el diagnóstico hepático específico
Lee et al. Nanoglue: an alternative way to display cell-internalizing peptide at the spikes of hepatitis B virus core nanoparticles for cell-targeting delivery
Yuan et al. Virus-like particle-based nanocarriers as an emerging platform for drug delivery
CN107029239A (zh) 一种多功能靶向分子及其用途
EP3145540B1 (en) Chemically activated nanocapsid functionalized for cancer targeting
CN109517843A (zh) 一种跨屏障靶向病灶的递药系统、载体系统及宿主细胞系统
Bajaj et al. Engineering virus capsids into biomedical delivery vehicles: structural engineering problems in nanoscale
CN116804049A (zh) 铁蛋白示踪多肽缀合物及其用途
Kiong et al. Development of Multilayer Nanoparticles for the Delivery of Peptide-Based Subunit Vaccine against Group A Streptococcus. Pharmaceutics [Internet]. 2022 Oct 1 [cited 2024 Jun 8]; 14 (10)
JP2008162981A (ja) ビオチン化ないしホーミングペプチド提示型バイオナノカプセル
WO2025012364A1 (en) Compositions of pneumococcal antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100406

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100428

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130514

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4509999

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees